Helius Medical Technologies Advances Stroke Rehabilitation with PoNS
Helius Medical Technologies' Breakthrough with PoNS Device
Helius Medical Technologies, Inc. (NASDAQ: HSDT), a pioneering neurotech company, heralds a significant advancement in the quest for better therapeutic options for individuals grappling with balance and gait deficits after strokes. They recently announced promising results from the Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP), signaling a potential FDA submission for an indication targeting chronic stroke patients.
Positive Trial Outcomes Show Efficacy
The clinical trials conducted under the SRP have produced encouraging results. A double-blind randomized controlled trial met its primary endpoint, showing substantial improvements in gait and balance deficits among stroke survivors using the active PoNS therapy. Notably, these trials demonstrated a low occurrence of adverse events, reinforcing the safety profile of this innovative treatment.
Enhanced Therapeutic Options for Patients
Dr. Antonella Favit-Van Pelt, the Chief Medical Officer at Helius, emphasized the importance of these findings, stating, "The successful execution of the PoNS SRP and the positive outcomes of our clinical trials represent a crucial milestone in enhancing the standard of care for stroke survivors. This therapy offers a valuable rehabilitation tool, enabling individuals to regain their balance and functional abilities." Helius is excited to discuss the detailed results from these studies in the near future.
Structure of the Stroke Registrational Program
Initiated in early 2024 with a strategic plan established during conversations with the FDA, the SRP comprises two pivotal studies: a double-blind randomized controlled trial and a single-arm trial. Clinicians are rigorously investigating the efficacy and safety of the PoNS device for patients with chronic stroke-related gait deficits.
Research and Participant Engagement
With 159 patients enrolled across the trials, over 130 participants successfully completed the treatment regimen and the subsequent follow-up phase. The trials spanned ten clinical sites, including renowned stroke rehabilitation centers located throughout the United States and Canada. Each study participant engaged in a combined treatment approach involving physical therapy and either the active or sham PoNS treatment.
Statistics Behind Stroke Impact
Staggeringly, over 7 million individuals suffer from stroke symptoms; approximately 80% face challenges with balance and mobility, culminating in an immense market opportunity for effective solutions. CEO Dane Andreeff remarked on the readiness of the team to present these findings to the FDA, adding, "We aspire for our submission to yield a successful outcome, ultimately providing an impactful therapeutic option for those enduring the repercussions of a stroke."
About PoNS and Its Deployment
The Portable Neuromodulation Stimulator (PoNS) represents a groundbreaking, non-invasive treatment modality designed to improve balance and mobility through neurostimulation via a mouthpiece. Currently, the device is authorized in Canada for treating gait deficits associated with stroke, multiple sclerosis (MS), and mild traumatic brain injuries. In the United States, it is indicated as a short-term treatment for MS symptoms and is used alongside supervised therapeutic exercise programs.
Looking Toward the Future
Helius Medical Technologies continues its commitment to innovation within the neurotech field, promoting neuroplasticity and functional rehabilitation. With ongoing research and the proactive engagement of the FDA, the company aims to bring the transformative benefits of the PoNS device to more patients. For further details on ongoing initiatives and updates, follow Helius Medical Technologies.
Frequently Asked Questions
What is the PoNS device?
The Portable Neuromodulation Stimulator (PoNS) is a device that delivers mild electrical impulses to the tongue, aiding in rehabilitation for balance and gait deficits.
Who can benefit from the PoNS therapy?
This therapy is primarily aimed at patients experiencing gait and balance deficits due to chronic stroke and other neurologic conditions like multiple sclerosis.
What were the outcomes of the recent clinical trials?
The trials demonstrated significant improvements in gait and balance in stroke patients, showcasing the efficacy and safety of the PoNS device.
What is the next step for Helius Medical Technologies with the FDA?
Helius plans to submit their application to the FDA for the PoNS device, seeking approval for its use in stroke rehabilitation.
Where can I find more information about Helius Medical Technologies?
For additional information, visit Helius Medical Technologies' website at www.heliusmedical.com.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
